Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 17, 2013

Teva Snaps Up MicroDose Therapeutx in Up To $165M Deal

  • Teva Pharmaceutical Industries is acquiring MicroDose Therapeutx, a pharma and drug delivery firm focused on inhalation technologies and products for lung diseases like asthma and COPD, as well as respiratory viruses and infections.

    Teva is slated to acquire all of MicroDose’s outstanding shares for $40 million, and will provide additional payments of up to $125 million upon the achievement of regulatory and development milestones, plus sales-based milestones and tiered royalty payments upon commercialization of MDT-637—the acquisition target’s lead candidate, for candidate respiratory syncytial virus (RSV)—and an earlier stage asthma/COPD medicine.

    “I am thrilled that Teva can now count the exciting MicroDose products and technologies amongst our growing respiratory portfolio,” Michael Hayden, M.D., Ph.D., CSO and president, Teva Global R&D, said in a statement.

    Added MicroDose president, CEO, and chairman Anand V. Gumaste: “We believe this agreement provides a unique opportunity to advance MicroDose’s platform technology and development programs for the greatest benefit of patients. Teva has a strong and growing franchise in respiratory diseases, with extensive experience in both delivery mechanisms and novel therapeutic modalities."

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »